Innovent Presents P-III (CREDIT-1) Trial Results of Tafolecimab for Non-Familial Hypercholesterolemia at AHA 2022
Shots:
- The P-III (CREDIT-1) trial evaluates tafolecimab (450/600mg, q4w/q6w, SC) vs PBO (q4w/q6w) in a ratio (2:2:1:1) in 804 patients with non-FH. The product is expected to be available in 2023
- The results showed a treatment difference of mean change in LDL-C level from baseline to 48wk. was –65.0% with tafolecimab 450mg, q4w group and –57.3% with 600mg, q6w, 87.8% with tafolecimab (450mg, q4w) achieved ≥50% reduction from baseline to 48wk. in LDL-C levels; 91.7% achieved LDL-C <1.8 mmol/L; 83.4% LDL-C <1.4 mmol/L
- 82.1% with tafolecimab (600mg, q6w) achieved LDL-C <1.8 mmol/L; 68.7% LDL-C <1.4 mmol/L, reductions in non-HDL-C, ApoB & Lp(a) levels in both dose regimens of tafolecimab, was well tolerated & the safety profile was similar to other PCSK9 mAbs
Ref: PRNewswire | Image: Innovent
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
